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Complement Activation in Patients With Probable Systemic 
Lupus Erythematosus and Ability to Predict Progression 
to American College of Rheumatology–Classified Systemic 
Lupus Erythematosus
Rosalind Ramsey-Goldman,1 Roberta Vezza Alexander,2 Elena M. Massarotti,3 Daniel J. Wallace,4 Sonali Narain,5 
Cristina Arriens,6  Christopher E. Collins,7 Amit Saxena,8 Chaim Putterman,9 Kenneth C. Kalunian,10 
Tyler O’Malley,2 Thierry Dervieux,2 and Arthur Weinstein11
Objective. To evaluate the frequency of cell- bound complement activation products (CB- CAPs) as a marker of 
complement activation in patients with suspected systemic lupus erythematosus (SLE) and the usefulness of this bio-
marker as a predictor of the evolution of probable SLE into SLE as classified by the American College of Rheumatology 
(ACR) criteria.
Methods. Patients in whom SLE was suspected by lupus experts and who fulfilled 3 ACR classification criteria 
for SLE (probable SLE) were enrolled, along with patients with established SLE as classified by both the ACR and the 
Systemic Lupus International Collaborating Clinics (SLICC) criteria, patients with primary Sjögren’s syndrome (SS), 
and patients with other rheumatic diseases. Individual CB- CAPs were measured by flow cytometry, and positivity 
rates were compared to those of commonly assessed biomarkers, including serum complement proteins (C3 and C4) 
and autoantibodies. The frequency of a positive multianalyte assay panel (MAP), which includes CB- CAPs, was also 
evaluated. Probable SLE cases were followed up prospectively.
Results. The 92 patients with probable SLE were diagnosed more recently than the 53 patients with established 
SLE, and their use of antirheumatic medications was lower. At the enrollment visit, more patients with probable SLE 
were positive for CB- CAPs (28%) or MAP (40%) than had low complement levels (9%) (P = 0.0001 for each). In prob-
able SLE, MAP scores of >0.8 at enrollment predicted fulfillment of a fourth ACR criterion within 18 months (hazard 
ratio 3.11, P < 0.01).
Conclusion. Complement activation occurs in some patients with probable SLE and can be detected with higher 
frequency by evaluating CB- CAPs and MAP than by assessing traditional serum complement protein levels. A MAP 
score above 0.8 predicts transition to classifiable SLE according to ACR criteria.
INTRODUCTION
Systemic lupus erythematosus (SLE) is a clinically hetero-
geneous autoimmune disease characterized by the presence of 
diverse autoantibodies and activation of the complement system 
(1). The classification criteria for SLE by the American College of 
Rheumatology (ACR) (2) and more recently by the Systemic Lupus 
International Collaborating Clinics (SLICC) (3)—both developed 
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for research purposes (3,4)—recognize this clinical and laboratory 
heterogeneity. Low levels of serum complement protein (C3 and 
C4) are included in the SLICC criteria as well as the classifica-
tion criteria newly developed by the European League Against 
Rheumatism (EULAR) and the ACR (5), due to the relatively high 
specificity of complement activation leading to low serum com-
plement in SLE (6).
Despite the specificity of hypocomplementemia, its frequency 
in SLE is low (1). We have previously shown that complement acti-
vation, measured reliably by assessing cell- bound complement 
activation products (CB- CAPs), especially C4d bound to eryth-
rocytes (EC4d) and to B lymphocytes (BC4d), can be detected 
in SLE with greater frequency than by assessing high anti– 
double- stranded DNA (anti- dsDNA) and low serum complement 
proteins (7,8).
Many patients with suspected SLE who do not fulfill ACR cri-
teria have been designated as having “probable, possible, latent, 
or incomplete” SLE (9–12). There is no consensus definition or 
nomenclature for these patients (13). However, some patients 
develop classifiable SLE over time (9–11). Currently, there are no 
biomarkers to reliably distinguish who, among patients with prob-
able SLE, will develop SLE by classification criteria. However, early 
diagnosis and appropriate intervention may prevent lupus flares 
and more serious organ inflammation (9,14,15).
We hypothesized that probable SLE which ultimately devel-
ops into classifiable SLE may have detectable complement 
activation (1). Therefore, we conducted a cross- sectional and 
prospective study of patients with probable SLE to determine the 
frequency of elevated CB- CAPs in these patients and whether 
the presence of CB- CAPs, measured either directly or within a 
multianalyte assay panel (MAP), is predictive of development of 
classifiable SLE.
PATIENTS AND METHODS
Study populations. Adult patients were enrolled, in com-
pliance with the Helsinki Declaration, from 2015 to 2017. Central 
or internal review boards at 7 academic institutions approved the 
study, and all subjects provided informed consent. Patients were 
recruited from lupus cohorts and faculty practices overseen by an 
experienced SLE investigator.
Patients with SLE fulfilled both the ACR classification criteria 
(2) and the SLICC classification criteria (3) for SLE at enrollment. 
Patients with probable SLE were enrolled if they fulfilled 3 ACR 
criteria, irrespective of whether they fulfilled the SLICC criteria, 
and if the investigator had a high suspicion of the diagnosis of 
lupus. Patients with probable SLE could not be enrolled if they 
had proteinuria of >200 mg or biopsy- proven lupus nephri-
tis. Investigators were asked to examine the historic electronic 
records for clinical, hematologic, and immunologic features. The 
date of diagnosis for probable SLE was the date on which the 
third ACR criterion was confirmed.
Patients with probable SLE were followed up prospectively, 
and 69 patients had a first follow- up visit 9–18 months after 
 enrollment. Investigators determined whether patients met a 
fourth ACR criteria at the follow- up visit and the approximate date 
that classifiable SLE occurred, either at or prior to evaluation.
Disease activity was measured in SLE and probable SLE 
using the Safety of Estrogens in Lupus Erythematosus National 
Assessment (SELENA) version of the SLE Disease Activity Index 
(SLEDAI) (16). Low complement and anti- dsDNA levels were 
scored if they were shown to be abnormal in the central clinical 
laboratory (Exagen, Vista, CA). Nonserologic SELENA–SLEDAI 
was calculated by excluding the anti- dsDNA and complement 
components from the score.
This study also included patients with primary Sjögren’s 
syndrome (SS) and other well- defined rheumatic diseases, who 
served as controls. For the latter group (n = 51), clinical diagnosis 
was based on the expert opinion of the investigators, and the 
group included patients with rheumatoid arthritis (RA) (n = 31), 
psoriatic arthritis (n = 10), dermatomyositis (n = 4), juvenile idio-
pathic arthritis (n = 3), systemic sclerosis (n = 2), and ankylosing 
spondylitis (n = 1). Diagnosis of SS was based on a modification of 
the ACR criteria for SS (17), and patients were enrolled if positive 
for 2 of following 3 features: 1) current keratoconjunctivitis sicca in 
≥1 eye with either an ocular staining score of ≥3 or a Schirmer’s 
test result of ≤5 mm in 5 minutes; 2) labial or salivary biopsy with 
a positive focus score (≥1 focus/4 mm2); 3) positive serum anti- 
SSA/Ro and/or anti- SSB/La and antinuclear antibody (ANA) titer 
of ≥1:80 determined by immunofluorescence assay (IFA).
Each of the 7 sites recruited patients with SLE, probable SLE, 
and other rheumatic diseases; patients with SS were recruited at 
6 sites. Case report forms from the enrollment visit of all patients 
with probable SLE and 32 randomly selected patients with SLE 
were reviewed and adjudicated by a lupus expert clinician (KCK) 
not affiliated with any institution enrolling patients in the study. 
Case report forms from the probable SLE patient follow- up vis-
its were adjudicated by 2 of the authors (KCK [n = 52] and AW 
[n = 17]) without knowledge of the results of the laboratory tests 
performed by Exagen (see below). The adjudicators assessed 
clinical features and routine laboratory tests, including complete 
blood cell counts and urinalyses, and the investigators were often 
asked to provide additional records as needed.
Patients provided venous blood samples that were collected 
in EDTA- containing tubes and serum separator tubes at all vis-
its. Specimens were shipped overnight to Exagen for diagnostic 
immunology testing.
Biomarker analysis. ANA was measured using an 
enzyme- linked immunosorbent assay (ELISA) (QUANTA Lite; 
Inova Diagnostics) and indirect IFA (NOVA Lite; Inova Diagnostics) 
as described previously (8,18). Anti- dsDNA antibodies were also 
measured by ELISA and were confirmed using an IFA with Crithidia 
luciliae (8,18). Autoantibodies to extractable nuclear antigens 
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(anti- Sm, anti- SSB/La, anti- SSA/Ro, anti- CENP, anti–Jo- 1, and 
anti–Scl- 70), anti–cyclic citrullinated peptide (anti- CCP) antibodies, 
and rheumatoid factor (RF) were measured using the EliA test on 
the Phadia 250 platform (ThermoFisher Scientific) (19). The IgG, 
IgM, and IgA isotypes of anti cardiolipin and anti–β2- glycoprotein I, 
and the IgG isotype of anti- phosphatidylserine/prothrombin were 
measured using chemiluminescence immunoassay or ELISA.
Serum complement proteins C3 and C4 were measured by 
standard immunoturbidimetry assay (The Binding Site) (19) and 
were considered low if they were below the manufacturer’s cutoff 
levels (81.1 mg/dl and 12.9 mg/dl, respectively). Individual CB- CAPs 
(EC4d and BC4d) were measured by quantitative flow cytometry 
and expressed as net mean fluorescence intensity (MFI), as previ-
ously described (8,19). CB- CAP positivity was determined by a net 
MFI of >14 for EC4d and/or a net MFI of >60 for BC4d. Assessment 
of CB- CAPs was not available for 3 patients (2 SLE and 1 SS) at 
enrollment. These patients were included in all other analyses.
The MAP with algorithm, which included EC4d, BC4d, ANA, 
anti- dsDNA, anti- Sm, as well as other lupus and non- lupus autoan-
tibodies, was evaluated as described in detail elsewhere (8,18,19). 
MAP assessment was not available for 3 patients (1 SLE, 1 prob-
able SLE, and 1 SS) at enrollment; these subjects were included 
in all other analyses. For 1 of the follow- up visits, BC4d and MAP 
determination was not available; this visit was included in all other 
analyses.
Statistical analysis. Statistical comparisons were con-
ducted using unpaired t- test, Mann- Whitney test, Fisher’s exact 
test, chi- square test, or McNemar’s test, as appropriate (Graph-
Pad). Sensitivity, specificity, positive and negative  likelihood 
Figure 1. American College of Rheumatology (ACR) criteria for systemic lupus erythematosus (SLE) at enrollment. Clinical and immunologic 
1997 ACR criteria were evaluated in the entire population of patients with SLE and patients with probable SLE (pSLE) (A) and in the probable 
SLE subgroups fulfilling or not fulfilling the 2012 Systemic Lupus International Collaborating Clinics (SLICC) criteria (B) at enrollment. All criteria, 
including antinuclear antibody (ANA) and immunologic criteria, refer to historical positivity. The average number of ACR criteria fulfilled by the 
patients with SLE was 5.3, while those with probable SLE fulfilled 3 ACR criteria (per study protocol). Statistically significant differences are 
indicated with P values, obtained by Fisher’s exact test.
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ratios (LRs) (8,18), and the Youden index (J = [sensitivity 
+ specificity] − 1) (20,21), which is a measure of diagnostic 
accuracy of a test compared to other tests, were also calcu-
lated. Confidence intervals of the LRs were calculated using 
the Miettinen and Nurminen method (Analyse- it Software). For 
statistical analysis, MAP- indeterminate assessments (14 sub-
jects) and equivocal assessments (8 subjects) at enrollment 
were considered positive or negative based on their actual 
MAP score value.
Follow- up data on the patients with probable SLE were 
analyzed using Fisher’s exact test and a Kaplan- Meier curve 
with log rank test and Cox proportional hazards model (Med-
Calc Software), for time to fulfillment of the fourth ACR criterion. 
 Analyse- it software was used for the receiver operating charac-
teristics curve and decision plot analyses.
RESULTS
Study populations. Baseline. A total of 246 patients were 
included in this study: 53 patients with SLE, 92 with probable 
SLE, 50 with SS, and 51 with other rheumatic diseases. Of the 
92 patients with probable SLE, 35 (38%) met the SLICC clas-
sification criteria at enrollment. Patients who did not meet the 
criteria for study enrollment or for whom the adjudicator could 
not make a definite determination were excluded from the study, 
and follow- up visits were not required (see Supplementary 
Table 1, on the Arthritis & Rheumatology web site at http://onlin e 
libr ary.wiley.com/doi/10.1002/art.41093/ abstract).
The demographic characteristics at enrollment of all sub-
jects are reported in Supplementary Table 2 (http://onlin e 
libr ary.wiley.com/doi/10.1002/art.41093/ abstract). A higher per-
centage of patients with probable SLE were white compared to 
patients with SLE (P = 0.002). The mean number of years since 
diagnosis of probable SLE was lower than that of SLE (3.6 ± 4.9 
years and 9.6 ± 9.4 years, respectively; P = 0.0001), which is 
consistent with the possibility that patients with probable SLE 
were enrolled early in their disease. The demographic charac-
teristics of patients with probable SLE who fulfilled the SLICC 
criteria were similar to those of patients who did not.
The ACR criteria and the SLICC criteria fulfilled by the SLE 
and probable SLE patients at enrollment are reported in Figure 1 
and Figure 2. According to study protocol, all subjects fulfilled 
the criterion of historical ANA positivity, and none of the patients 
with probable SLE had renal proteinuria.
Consistent with findings from other studies (12,22–24), 
the most common ACR clinical criteria fulfilled by patients with 
SLE and patients with probable SLE were arthritis (77% and 
50%, respectively) and hematologic disorder (72% and 41%), 
while the most common SLICC clinical criterion was synovitis 
(75% and 47%). Patients with SLE had more mucosal ulceration, 
serositis, hematologic features, and immunologic features than 
patients with probable SLE.
Fulfillment rates of individual ACR criteria (Figure  1B) and 
SLICC criteria (Figure 2B) were similar among patients with prob-
able SLE who did or did not satisfy SLICC classification criteria, 
apart from historical low complement levels and alopecia. The 
presence of historical anti- Sm antibodies approached signifi-
cance (P = 0.052) (Figure 2B).
Disease activity in both patients with SLE and patients 
with probable SLE was mild at enrollment (see Supplementary 
Data and Supplementary Table 3, http://onlin elibr ary.wiley.com/
doi/10.1002/art.41093/ abstract). Hydroxychloroquine (HCQ) and 
prednisone use were significantly lower in patients with proba-
ble SLE compared to patients with SLE, despite the physician’s 
opinion that the patients with probable SLE likely had SLE (Sup-
plementary Figures 1A and 1B, http://onlin elibr ary.wiley.com/
doi/10.1002/art.41093/ abstract).
Follow- up. Sixty-nine patients with probable SLE com-
pleted a follow-up visit 9–18 months after enrollment. 
Follow-up visits were conducted at all sites, and there were 
no differences in age, sex, time since diagnosis, race/ethnicity, 
or fulfillment of SLICC criteria or individual ACR criteria be-
tween the group of patients who had a follow- up visit in this 
time frame (n = 69) and those who did not (n = 23) (data not 
shown). Disease activity was slightly higher in the group that 
did not attend a follow- up visit (nonserologic SELENA–SLEDAI 
2.09 versus 1.09; P = 0.04).
Of the 69 patients who completed a follow- up visit, 20 (29%) 
fulfilled ≥1 additional ACR criterion. Hematologic disorder was the 
criterion fulfilled with highest frequency (50%), followed by oral 
ulcers (19%), immunologic disorder (8%), serositis (8%), arthri-
tis (8%), photosensitivity (4%), and rash (4%). Of the 13 patients 
who fulfilled an additional hematologic criterion at follow- up, 10 
had lymphopenia as their sole feature. Of these, 3 were receiving 
 medications that might have affected lymphocyte counts: azathi-
oprine 50 mg/day, methotrexate 15 mg/week, and/or mycophe-
nolate 2,000 mg/day plus prednisone 2.5 mg/day. Investigators 
concluded that the lymphopenias were due to SLE.
Fulfillment of the SLICC criteria at enrollment did not 
 predict fulfillment of the ACR criteria 18 months later. Of the 
69 patients with probable SLE who completed a follow- up 
visit, 26 (38%) had fulfilled SLICC criteria at enrollment and 43 
(62%) had not. Ten of the 26 patients with probable SLE who 
had fulfilled SLICC at enrollment (38.5%) acquired additional 
ACR classification criteria versus 10 of the 43 (23.3%) who 
had not fulfilled SLICC criteria at enrollment (P = 0.27). In addi-
tion, fulfillment of the SLICC criteria at baseline did not lead to 
faster fulfillment of the ACR criteria (P = 0.19 by Cox regres-
sion) (Supplementary Table 4, http://onlin elibr ary.wiley.com/
doi/10.1002/art.41093/ abstract). Six patients converted from 
SLICC criteria–negative to SLICC criteria–positive at follow- up, 
5 of whom also  transitioned to ACR- classifiable SLE.
The number of organ manifestations at enrollment did not 
 contribute to progression. Among the 69 patients with probable 
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SLE who had a follow- up visit, 41 (59%) had 1 organ man ifesta-
tion  (including hematologic, excluding immunologic), and 28 
(41%) had 2. Of the 41 patients with 1 organ involved, 14 (34%) 
transitioned to classifiable SLE, whereas of the 28 patients with 
2 organs involved, 6 (21%) transitioned. This difference was not 
significant (P = 0.29).
At follow- up, HCQ use increased from 63% to 74%. Among 
the 20 patients who converted to classifiable SLE, HCQ use 
increased from 75% to 80% (data not shown).
Biomarker analysis at baseline and follow- up. 
Most patients with SLE and probable SLE were ANA- positive 
on the day of the enrollment visit (Table  1). The ANA IFA 
assay used in this study was more sensitive than an ELISA in 
most cases, although ANA positivity is known to vary greatly 
depending on the assay platform or kit used (25,26). Spec-
ificity of ANA for SLE was low, while anti- dsDNA had a high 
specificity for SLE, as 2% of the patients with SS and none 
of the patients with other diseases were anti- dsDNA–positive. 
Figure 2. SLICC criteria for SLE at enrollment. Clinical and immunologic 2012 SLICC criteria were evaluated in the entire population of 
patients with SLE and patients with probable SLE (A) and in the probable SLE subgroups fulfilling or not fulfilling the SLICC criteria (B) at 
enrollment. All criteria, including ANA and immunologic criteria, refer to historical positivity. The average number of SLICC criteria fulfilled by the 
patients with SLE and the patients with probable SLE was 7.2 and 3.8, respectively. The average number of SLICC criteria was higher in the 
35 patients with probable SLE who fulfilled these classification criteria, compared to the 57 patients who did not (4.8 versus 3.2, respectively). 
Statistically significant differences are indicated with P values, obtained by Fisher’s exact test. Anti- dsDNA = anti–double- stranded DNA (see 
Figure 1 for other definitions).
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Anti- dsDNA sensitivity was low for SLE (38%) and even lower 
for probable SLE (11%), although among patients with proba-
ble SLE, positivity for anti-dsDNA was more frequent in those 
who fulfilled the SLICC criteria than in those who did not (20% 
versus 5%; P = 0.039). Unsurprisingly, anti- SSA and anti- SSB 
positivity rates were highest among SS patients (27), whereas 
RF and anti- CCP positivity was observed mainly in RA patients 
(28) (Table 1).
Although a high percentage of patients with SLE and 
probable SLE had historically low complement levels (64% 
and 36%, respectively) (Figure  2), complement protein levels 
were low on the day of enrollment in a minority of patients with 
SLE and probable SLE (23% and 9%), respectively) (Table  1), 
consistent with findings from previous studies (8,18). At base-
line, anti- C1q antibodies were present in 34% of patients with 
SLE and 13% of patients with probable SLE. Other plasma 
complement- related markers were not measured. The positiv-
ity rate for antiphospholipid antibodies with isotypes was 25% 
in SLE, 17% in probable SLE, 10% in SS, and 8% in other 
diseases. None of these biomarkers individually or in combi-
nation were significantly associated with transition of probable 
SLE to classifiable SLE (Supplementary Table 4, http://onlin e 
libr ary.wiley.com/doi/10.1002/art.41093/ abstract).
The frequency of CB- CAP positivity was higher than that of 
low complement levels in both SLE and probable SLE (P = 0.0001 
for both) (Table 1). In probable SLE, this was true whether or not 
patients fulfilled the SLICC criteria. The difference between the 
rate of low complement levels and the rate of CB- CAP positivity 
in probable SLE was especially large in the subgroup not fulfill-
ing the SLICC criteria (2% and 18% respectively; P < 0.008). In 
addition, CB- CAP positivity demonstrated higher sensitivity than 
anti- dsDNA positivity in probable SLE (P < 0.0005).
MAP positivity, unlike CB- CAP positivity, was equally distrib-
uted between the subgroups fulfilling or not fulfilling the SLICC cri-
teria (Table 1). The MAP algorithm includes biomarkers (in addition 
to CB- CAPs) that increase its diagnostic sensitivity for SLE, but 
may not correlate as closely with low serum complement levels 
as with CB- CAPs alone.
More patients with probable SLE were white than black (61% 
versus 16%), while patients with SLE were more racially diverse 
(34% white versus 38% black) (Supplementary Table 2, http://
onlin elibr ary.wiley.com/doi/10.1002/art.41093/ abstract). Positivity 
for CB- CAPs was more common in black patients with SLE and 
 probable SLE (SLE: white 56%, black 68%; probable SLE: white 
21%, black 33%), but this difference was not statistically significant.
The MAP demonstrated higher sensitivity at enrollment than 
low complement levels in SLE (77% versus 23%) and in probable 
SLE (40% versus 9%) (P = 0.0001 for both) and higher positive 
LRs for SLE and probable SLE (Tables 1 and 2). The MAP was also 
more sensitive (P < 0.05) and more specific than positive  CB- CAPs 
in probable SLE (Tables 1 and 2). Specificity of the MAP versus 
all patients with other autoimmune rheumatic diseases (n = 101, 
including SS) was 85% (data not shown).
Since the specificity of anti- dsDNA for SLE compared to the 
group of patients with other diseases, excluding SS, was 100% 
(leading to infinite positive LRs for SLE and probable SLE), an 
adjusted specificity of 97.5% was used for the calculation of these 
LRs (18). Although, as expected, the positive LR of anti- dsDNA 
was strong for SLE (>15.1), it was moderate for probable SLE 
(>4.35), due to its low sensitivity (11%). The positive LR of the MAP 
Table 1. Diagnostic assay results for patients with SLE, probable SLE, SS, and other rheumatic diseases at enrollment*
Biomarker
SLE 
(n = 53)
Probable SLE 
(n = 92)
Probable SLE/ 
SLICC- positive 
(n = 35)
Probable SLE/ 
SLICC- negative 
(n = 57)
SS 
(n = 50)
Other rheumatic 
diseases 
(excluding RA) 
(n = 20)
RA only 
(n = 31)
Low complement 
levels†
23 9 20 2 2 0 3
CB- CAPs‡ 61 28 46 18 10 10 16
MAP 77 40 49 34 27 5 3
ANA (IFA) 91 92 97 89 88 75 74
ANA (ELISA) 91 82 86 79 92 40 65
Anti- dsDNA§ 38 11 20 5 2 0 0
Anti- Sm 19 4 9 2 0 0 0
Anti- SSA/Ro 47 30 26 33 76 0 0
Anti- SSB/La 9 9 6 11 34 0 0
RF (IgM) 11 16 20 14 36 10 68
RF (IgA) 8 9 3 12 34 0 42
Anti- CCP 4 1 0 2 6 0 71
* Values are percentages. SLE = systemic lupus erythematosus; SS = Sjögren’s syndrome; SLICC = Systemic Lupus International Collab-
orating  Clinics; RA = rheumatoid arthritis; CB- CAPs = positive cell- bound complement activation products; MAP = multianalyte assay 
panel; ANA = antinuclear antibody; anti- dsDNA = anti–double- stranded DNA; RF = rheumatoid factor; anti- CCP = anti–cyclic citrullinated 
peptide. 
† C3 and/or C4. 
‡ Elevated C4d bound to erythrocytes (EC4d) (mean fluorescence intensity [MFI] >14) and/or BC4d (MFI >60). 
§ Measured by enzyme- linked immunosorbent assay (ELISA) and confirmed by immunofluorescence assay (IFA). 
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was higher than that of low complement and anti- dsDNA for both 
SLE and probable SLE (Table 2), indicating that a positive MAP 
increases the posttest probability of lupus more than the positivity 
of any individual biomarker.
The MAP was associated with a moderate negative LR 
(0.24 in SLE and 0.63 in probable SLE), indicating that a nega-
tive test has moderate ability to reduce the likelihood of the diag-
nosis of SLE or probable SLE. Nonetheless, the MAP yielded 
a negative LR lower than that obtained with complement and 
anti- dsDNA levels in both SLE and probable SLE. Therefore, the 
MAP and positive CB- CAPs had greater diagnostic accuracy as 
demonstrated by a higher Youden index (J score) than did low 
complement levels and anti- dsDNA in SLE and probable SLE 
(Table 2).
At follow- up, positivity for CB- CAPs (n = 69) decreased 
from 30% to 17% (P = 0.01) and positivity for the MAP (n = 68) 
decreased from 41% to 32% (P = 0.05). Nonsignificant decreases 
in disease activity were seen in mean SELENA–SLEDAI scores 
(from 1.63 to 1.21; P = 0.54) and in mean nonserologic SELENA–
SLEDAI scores (from 1.1 to 0.8; P = 0.65).
Only 2% of SS patients had low complement levels, while 
CB- CAPs were elevated in 10% of these patients, and 27% had 
a positive MAP score (Table 1). In patients with SS, positive and 
negative LRs for the MAP were 6.77 and 0.76, respectively, and 
the Youden index was 0.23 (data not shown).
We evaluated whether positivity for CB- CAPs, MAP, or 
other biomarkers at enrollment predicted fulfillment of the 
ACR classification criteria in the probable SLE population at 
Table 2. Performance of biomarkers for SLE and probable SLE at enrollment*
SLE (n = 53) Probable SLE (n = 92)
Specificity, 
% 
Sensitivity, 
% 
LR+ 
(95% CI)
LR− 
(95% CI) J
Sensitivity, 
%
LR+ 
(95% CI)
LR− 
(95% CI) J
Anti- dsDNA† 38 >15.1 (5.34–∞) 0.64 (0.49–0.74) 0.38 11 >4.35 (1.52–∞) 0.91 (0.81–0.98) 0.11 100
Low complement 
levels‡
23 11.5 (2.06–68.2) 0.79 (0.66–0.90) 0.21 9 4.43 (0.76–27.05) 0.93 (0.85–1.02) 0.07 98
CB- CAPs§ 61 4.43 (2.26–6.18) 0.45 (0.31–0.63) 0.47 28 2.06 (1.0–4.42) 0.83 (0.70–1.0) 0.15 86
MAP 77 19.6 (5.73–71.54) 0.24 (0.12–0.38) 0.73 40 10.1 (2.91–37.25) 0.63 (0.52–0.74) 0.36 96
* Specificity of biomarkers for SLE and probable SLE was calculated versus the group of patients with other rheumatic diseases (n = 51).  Specificity 
of anti- dsDNA was estimated at 97.5% for calculation of likelihood ratios (LRs). The upper limit of the 95% confidence interval (95% CI) of 
 anti- dsDNA (infinity) indicates 100% predictability. J = Youden index (see Table 1 for other definitions). 
† Measured by ELISA and confirmed by IFA. 
‡ C3 and/or C4. 
§ Elevated EC4d (MFI >14) and/or BC4d (MFI >60). 
Figure 3. Kaplan- Meier survival estimates in the cohort of patients with probable systemic lupus erythematosus (SLE) who had a follow- up 
visit within 18 months of enrollment. Kaplan- Meier survival curves show the percentage of patients with probable SLE who fulfilled American 
College of Rheumatology classification criteria during the 18- month follow- up period (time in days). Data on the 68 patients with probable SLE 
who had a follow- up visit 9–18 months after enrollment and for whom a multianalyte assay panel (MAP) score could be calculated are plotted. 
Group 1 (green line) represents the 16 patients with probable SLE with a MAP score of >0.8 at enrollment; group 0 (blue line) represents the 52 
patients with probable SLE with a MAP score of ≤0.8 at enrollment.
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follow- up visits 9–18 months after enrollment. A decision plot 
indicated that the optimal cutoff for MAP score, based on  the 
Youden index, was >0.8 (Supplementary  Figure 2, http://onlin e 
library.wiley.com/doi/10.1002/art.41093/ abstract). A similar plot 
for EC4d showed an MFI cutoff of >20 (data not shown).
Of the 20 patients with probable SLE who fulfilled the ACR 
classification criteria within 18 months, 8 (40%) had a MAP score 
of >0.8 at enrollment. Of the 48 patients (71%) who continued 
to be identified as having probable SLE at follow- up visits, only 
8 had a MAP score of >0.8 at enrollment (17%). The association 
between frequency of a MAP score of >0.8 at enrollment and 
fulfillment of the ACR criteria within 18 months approached sta-
tistical significance (P = 0.059).
We also evaluated time to fulfillment of ACR criteria in 
patients with probable SLE based on whether their MAP score at 
enrollment was above or below 0.8. Of the 69 visits, MAP scores 
could be analyzed for 68; at enrollment, 16 patients with prob-
able SLE had a MAP score of >0.8, and 52 had a MAP score 
of ≤0.8.  Figure 3 shows the Kaplan- Meier survival curves of the 
2 groups (P < 0.010), with a hazard ratio of 3.11 (95% confi-
dence interval 1.26–7.69). The hazard ratio of MAP scores was 
higher than that of other biomarkers (Table 3). Anti- dsDNA posi-
tivity and an EC4d MFI of >20 also showed higher hazard ratios 
(2.97 [P = 0.043] and 2.61 [P = 0.053], respectively) than that of 
low complement levels (Table 3). However, a MAP score of >0.8 
outperformed all the other measured biomarkers, including anti- 
DNA plus anti- Sm, low complement levels, and antiphospholipid 
antibodies (Table  3 and Supplementary Table 4, http://onlin e 
libr ary.wiley.com/doi/10.1002/art.41093/ abstract).
DISCUSSION
We assessed the frequency of positive CB- CAPs mea-
sured directly or within the MAP algorithm in patients with 
probable SLE compared to those with SLE and other autoim-
mune rheumatic diseases, and we evaluated the usefulness 
of these measures of complement activation as predictors of 
the evolution of probable SLE to classifiable SLE (according 
to ACR criteria). Our data suggest that CB- CAPs, measured 
directly or within the MAP algorithm, perform well as a poten-
tial test to support the diagnosis of SLE in patients with proba-
ble SLE. In particular, CB- CAPs and the MAP performed better 
than standard testing, which includes assessing antibodies to 
dsDNA or low serum complement levels. In addition, a MAP 
score of >0.8 was the best predictor that a patient with proba-
ble SLE would acquire a fourth ACR criterion within 18 months 
postenrollment.
It is well recognized that diagnosis relates to the prob-
ability of an illness in a specific symptomatic individual, in 
contrast to classification criteria, which are based on per-
formance characteristics, such as sensitivity and specificity 
(29,30). However, in the absence of diagnostic SLE guide-
lines, the classification criteria are often used to diagnose 
SLE (31). In a recent study of newly diagnosed lupus patients, 
with physician diagnosis as the gold standard, only 66.1% 
met ACR criteria and 83.5% met SLICC criteria; 89 patients 
(23%) fulfilled only 3 ACR criteria (32). Furthermore, while the 
SLICC criteria are more sensitive than the ACR criteria, they 
are somewhat less specific (33). This demonstrates a need for 
better diagnostic biomarkers.
Probable, incomplete, or latent lupus has been a diag-
nostic construct applied to patients who do not fulfill ACR 
classification criteria for SLE (34). Cohort studies have shown 
that in up to 20% of patients, probable SLE may progress 
to SLE that fulfills ACR classification criteria over a period of 
2–5 years, and some may develop organ damage (9,10,35). If 
patients who are more likely to have true incipient SLE can be 
identified at an early stage, decision-making regarding ther-
apeutic intervention may be improved For example, James 
et  al demonstrated that HCQ therapy delayed the onset of 
complete SLE in patients who had not yet been diagnosed 
(36). The patients with probable SLE in the current study were 
less likely to be treated with HCQ or prednisone compared 
to patients with SLE, despite fulfilling 3 ACR criteria and the 
belief by a physician experienced in lupus that SLE was a 
likely diagnosis.
Since we recruited patients from academic sites where 
large lupus cohorts were being followed up, the likelihood of an 
SLE diagnosis was based on expert opinion. We surmised that 
a higher percentage of these selected patients with probable 
SLE would be more likely to develop a fourth ACR criterion over 
2–3 years than those in a more loosely defined probable SLE 
group. This is supported by the observation that 35 of 92 patients 
with probable SLE (38%) who did not meet the ACR classification 
for SLE did meet the SLICC classification criteria at enrollment. 
This suggests that the investigators considered ≥1 SLICC feature 
in their evaluations to not be definitely related to SLE, since those 
patients could have been included in the SLE group instead of the 
probable SLE group. This also highlights an important difference 
between classification criteria and diagnosis. A similar  percentage 
Table  3. HRs of biomarkers predicting fulfillment of ACR 
classification criteria by 18 months in patients with probable SLE*
HR 95% CI P 
Anti- dsDNA† 2.97 0.98–8.99 0.043
Low complement 
levels‡
1.93 0.44–8.53 0.375
CB- CAPs§ 1.66 0.67–4.09 0.275
EC4d >20 MFI 2.61 0.99–6.88 0.053
MAP >0.8 3.11 1.26–7.69 0.0097
* Hazard ratios (HRs) of the biomarkers were calculated by Cox 
 regression. Data on 69 follow-up visits (n = 68 for MAP) that occurred 
9–18 months after enrollment were analyzed. ACR = American 
 College of Rheumatology (see Table 1 for other definitions). 
† Measured by ELISA and confirmed by IFA. 
‡ C3 and/or C4. 
§ Elevated EC4d (MFI >14) and/or BC4d (MFI >60). 
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of SLICC criteria fulfillment was found in a recently described 
cohort of patients who fulfilled 3 ACR cri teri a (37). Furthermore, 
in the present study, 29% of the 69 patients with a follow- up visit 
within 18 months acquired a fourth ACR criterion. This is a much 
higher rate in a shorter period of time than shown in prior studies 
(13,24).
We have confirmed findings of previous studies (7,8), demon-
strating that positive CB- CAPs measured directly and within the 
MAP algorithm are more sensitive biomarkers than low serum 
complement levels or anti- dsDNA antibodies in SLE. We report 
positive CB- CAPs in a significant number (28%) of patients with 
probable SLE, whereas low serum complement levels were pres-
ent in only 9% and anti- dsDNA in 11%. Furthermore, the MAP 
algorithm was positive in 77% of patients with SLE and in 40% 
of patients with probable SLE. This confirms our hypothesis and 
observations that complement activation is characteristic of SLE 
and can be detected more reliably by measuring activation prod-
ucts than serum complement component levels (1,8). We and 
others have shown that the presence of complement activation 
products closely correlates with active SLE (38,39).
The clinical and laboratory (immunologic) individual ACR and 
SLICC criteria in the probable SLE group versus the SLE group 
showed, as expected, a numerical and statistically significant lower 
incidence of many features, including arthritis, rashes, alopecia, 
serositis, and leukopenia. Conversely, there were few differences 
between the probable SLE subsets fulfilling SLICC criteria or not, 
except for alopecia and a history of low complement levels. How-
ever, C3 and C4 lack sensitivity as markers of complement activa-
tion in probable SLE, with only 9% showing hypocomplementemia 
at baseline. While 83% of the patients with probable SLE who 
fulfilled SLICC criteria had historically low complement levels, only 
20% presented with low levels at the time of testing. Even within 
the SLICC- positive subset, positive CB- CAPs and MAP were sig-
nificantly more frequent than low serum complement levels.
In this study, the presence of CB- CAPs (BC4d and/or EC4d) 
alone did not predict progression to classifiable SLE. However, a 
MAP score of >0.8 did predict progression, as did an EC4d MFI of 
>20 and anti- dsDNA positivity, although with lower hazard ratios. 
This may be related to the greater frequency of MAP positivity in 
probable SLE, since the cohort of patients followed up is rela-
tively small. A higher cutoff for the MAP index (0.8 versus 0.1) was 
needed to show prediction of developing ACR- classifiable SLE. 
This may be related to the lack of specificity of a lower index in this 
small cohort of patients with probable SLE who converted. EC4d 
alone (at a higher cutoff than what is used routinely [MFI of 20 
versus 14]) also showed a correlation with conversion, suggesting 
that complement activation is one key pathogenetic element in the 
evolution of SLE and is better detected by measurement of CB- 
CAPs directly or within the MAP than by low serum complement 
levels. We suggest that a longer follow-up, with potential evolu-
tion from probable SLE to SLE in more patients, might reveal that 
EC4d alone and the MAP would correlate with conversion even 
more significantly.
We also studied patients with SS, since they can exhibit 
numerous autoantibodies and low serum complement levels (40). 
We observed an increased frequency of positive CB- CAPs com-
pared to low serum complement levels (10% versus 2%) in SS 
patients, but these were not significantly different from frequencies 
in the control group with other rheumatic diseases. However, the 
MAP did show a higher positivity rate than in the control group 
(27% versus 4%), possibly because of the high titers of ANA found 
in our SS cohort (data not shown), which can influence the results 
of the algorithm. Since only 2% of the SS patients exhibited low 
serum C3 or C4 levels, it is possible that our group of 50 patients 
is not representative of the large cohorts that have been studied 
in the past (40).
A limitation of this study is the small cohort size of patients 
with probable SLE for whom we have follow- up data, as well 
as the relatively short follow- up period. However, 20 of the 
69 patients (29%) who had a follow- up visit within 18 months 
fulfilled a fourth ACR criterion in this time frame, confirming 
our expectation that this cohort from academic lupus centers 
might be more likely to progress to classifiable SLE than prior 
studies have suggested. Another limitation is that retrospec-
tive determination of whether patients fulfill classification crite-
ria is dependent on a comprehensive review of prior medical 
records and laboratory test results (including the presence of 
leukopenia or lymphopenia), and these may not have been 
available for all patients at every site. The adjudicators often 
requested and received additional records. However, the 
records we received may have been incomplete, as data on 
the lupus anticoagulant test, for example, were rarely reported. 
One strength of our study is that the probable SLE group is 
well defined and not classified by physician judgment alone.
In summary, our data show that positive CB- CAPs alone 
or in the MAP algorithm are present in a higher percentage 
of patients with SLE and patients with probable SLE com-
pared to antibodies to dsDNA or low serum complement lev-
els. The relatively high positivity rate of CB- CAPs and the 
MAP in the probable SLE group suggests that complement 
activation might occur early in the evolution of SLE and may 
be a feature in patients with suspected lupus. In addition, 
patients with probable SLE who had a MAP score of >0.8 or 
an EC4d MFI of >20 at enrollment were more likely to fulfill a 
fourth ACR criterion during a relatively brief follow- up; these 
biomarkers predicted the transition to SLE better than other 
clinical and laboratory parameters. The detection of comple-
ment activation in patients with probable lupus who do not 
fulfill ACR cri teria or even SLICC criteria could have impli-
cations with regard to treatment, as early appropriate ther-
apy in these patients may potentially slow the rate of disease 
 progression (36,41).
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